Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Solar Urticaria
Interventions
DRUG

Intravenous immunoglobulins

Single administration of 2 g/kg intravenous immunoglobulins over 2 days

Trial Locations (12)

14033

University Hospital, Caen

25000

Regional University Hospital, Besançon

30029

University Hospital, Nîmes

31059

University Hospital, Toulouse

34295

Regional University Hospital, Montpellier

35033

University Hospital, Rennes

38043

University Hospital, Grenoble

51092

University Hospital, Reims

54035

University Hospital, Nancy

59037

Regional University Hospital, Lille

75475

Saint louis Hospital, Paris

87042

University hospital, Limoges

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

collaborator

Saint-Louis Hospital, Paris, France

OTHER

lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT01360658 - Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria | Biotech Hunter | Biotech Hunter